NCT06815471

CRF2 Agonist for the Treatment of Worsening Heart Failure

The DSMB recommended pausing the enrollment to give time to the Executive Committee to revise the eligibility criteria to exclude patients who may be in impending cardiogenic shock or in other ways too ill to safely participate in the trial.